Compare Tripadvisor Inc Common Stock (TRIP) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tripadvisor Inc Common Stock vs 10X Genomics Inc — how do they compare? Tripadvisor Inc Common Stock trades at $8.77 (market cap $1.07B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: 10X Genomics Inc is far larger — about 8× Tripadvisor Inc Common Stock's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| TRIP | TXG | |
|---|---|---|
Market Cap | $1.07B | $8.55B |
Sector | Consumer Cyclical | Health |
52-Week High | $19.14 | $67.29 |
52-Week Low | $8.82 | $11.34 |
Enterprise Value | $1.12B | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tripadvisor (TRIP) trades at $9.085, down 2.57% for the day, reflecting ongoing pressure from recent earnings misses and competitive challenges. The stock shows bearish technical signals with mixed oscillators, while fundamentals reveal strong gross margins (92.11%) but thin net income (0.27%). Recent news highlights insider selling and TheFork subsidiary sale, creating uncertainty about growth prospects amid AI-driven travel competition.
The outlook remains cautious with analyst consensus leaning Hold (62.5%) despite a $11.80 price target suggesting 30% upside. Key risks include persistent earnings volatility, market share erosion to AI platforms, and declining cash flow trends. Investment opportunity hinges on Viator's performance and successful execution of strategic initiatives post-TheFork divestiture.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
